Document Classification

Section Type: RESULTS

Text: Despite similar improvements in metabolic control (HbA1c) after 24 weeks (-0. 8 + / -0. 9 % [pioglitazone] versus -0. 6 + / -0. 8 % [glimepiride] ; P = NS), carotid IMT was reduced only in the pioglitazone group after 12 weeks (-0. 033 + / -0. 052 versus -0. 002 + / -0. 047 mm [glimepiride] ; P < 0. 01 between groups) and 24 weeks (-0. 054 + / -0. 059 versus -0. 011 + / -0. 058 mm [glimepiride] ; P < 0. 005 between groups).